Back

The effect of Citrus reticulata peel extract containing hesperidin on inhibition of SARS-CoV-2 infection based on pseudovirus entry assays

Septisetyani, E. P.; Harsan, H. S.; Kumara, D.; Prasetyaningrum, P. W.; Paramitasari, K. A.; Cahyani, A. D.; Anam, K.; Kastian, R. F.; Santoso, A.; Ikawati, M.; Meiyanto, E.

2024-05-05 pharmacology and toxicology
10.1101/2024.05.03.592493 bioRxiv
Show abstract

Orange (Citrus reticulata Blanco) peel contains a flavonoid glycoside hesperidin (HSD) as the primary component. HSD, upon enzymatic hydrolysis, forms hesperetin (HST) aglycone derivate. These two flavonoids have been predicted to have in-silico affinities for ACE2 and SARS-CoV-2 spike, crucial proteins in SARS-CoV-2 infection mechanisms. However, in vitro antiviral testing of orange peel extract, HSD, and HST has not been reported. This study presents for the first time a pseudovirus entry assay approach to test the anti-SARS-CoV-2 effect of HSD, HST, and orange peel extract prepared by hydrodynamic cavitation (HCV). We used a non-virulent pseudovirus model as an alternative to the original virus to target the entry point and enable research to be conducted outside the BSL-3 facility. Based on HPLC analysis, the test results showed that HCV contained HSD at about 4% w/w. Moreover, HSD 1 and 10 M, HST 10 M, and HCV 1 g/ml showed inhibition of pseudovirus entry in 293/hACE2 cells with percentages inhibition 25.92, 37.40, 27.32, and 38.97 %, respectively. Despite HCV 1 g/ml showing about 6 % lower inhibitory activity than HSD 1 M in pseudovirus entry assay, it holds potential as a supplement or source of raw material for HSD as a SARS-CoV-2 antiviral.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 10%
18.8%
2
Molecules
39 papers in training set
Top 0.1%
12.1%
3
Pharmaceuticals
34 papers in training set
Top 0.1%
5.6%
4
Scientific Reports
3612 papers in training set
Top 15%
5.6%
5
Heliyon
152 papers in training set
Top 0.5%
5.2%
6
Frontiers in Pharmacology
111 papers in training set
Top 0.5%
4.9%
50% of probability mass above
7
Virology Journal
32 papers in training set
Top 0.1%
3.3%
8
Journal of Medical Virology
140 papers in training set
Top 0.7%
3.3%
9
Viruses
332 papers in training set
Top 2%
3.3%
10
International Journal of Biological Macromolecules
76 papers in training set
Top 0.5%
2.8%
11
Vaccines
198 papers in training set
Top 1%
2.4%
12
Antiviral Research
50 papers in training set
Top 0.4%
1.9%
13
International Journal of Molecular Sciences
494 papers in training set
Top 7%
1.9%
14
Journal of Translational Medicine
57 papers in training set
Top 0.7%
1.8%
15
eLife
5828 papers in training set
Top 52%
1.5%
16
Emerging Microbes & Infections
74 papers in training set
Top 1%
0.9%
17
European Journal of Pharmacology
15 papers in training set
Top 0.6%
0.9%
18
Virology
61 papers in training set
Top 1%
0.9%
19
Acta Tropica
13 papers in training set
Top 0.5%
0.9%
20
Journal of Immunology Research
12 papers in training set
Top 0.5%
0.9%
21
Life
29 papers in training set
Top 0.8%
0.9%
22
PLOS Neglected Tropical Diseases
466 papers in training set
Top 5%
0.9%
23
Biochemical and Biophysical Research Communications
84 papers in training set
Top 2%
0.9%
24
Gene
46 papers in training set
Top 2%
0.9%
25
Pharmacology Research & Perspectives
11 papers in training set
Top 0.4%
0.6%
26
Biomedicines
67 papers in training set
Top 3%
0.6%
27
BioMed Research International
28 papers in training set
Top 2%
0.6%
28
Acta Biochimica et Biophysica Sinica
23 papers in training set
Top 0.6%
0.6%